Dr. Califf Returns To US FDA: What To Do First?
Acting commissioner Janet Woodcock will remain at the agency and become principal deputy commissioner when Califf arrives.
You may also be interested in...
Robert Califf says there is a reason there is such a high turnover in the top post. He notes that the continuity and dedication of center directors is one of the reasons he returned.
After the boom of 2020 and 2021, the biotech sector is experiencing one of the deepest and longest downturns but there are hopes that catalysts could soon revive confidence.
The US FDA commissioner also suggests the pain medications along with marijuana products should be regulated differently than other drugs.